Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence
H Suzuki, S Akamatsu, M Shiota… - … Journal of Urology, 2024 - Wiley Online Library
Prostate cancer (PC) growth is hormone‐dependent and it frequently develops distant
metastases as disease progresses. Patients with metastatic castration‐sensitive prostate …
metastases as disease progresses. Patients with metastatic castration‐sensitive prostate …
Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids
N Ishii, S Hatakeyama, T Yoneyama, R Tanaka… - … Oncology: Seminars and …, 2022 - Elsevier
Objectives The effect of concomitant steroid use on the antibody response to a SARS-CoV-2
vaccine in patients with prostate cancer (PC) remains unknown. We aimed to evaluate the …
vaccine in patients with prostate cancer (PC) remains unknown. We aimed to evaluate the …
Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study
T Oishi, S Hatakeyama, R Tabata, D Fujimori… - The …, 2023 - Wiley Online Library
Background We aimed to evaluate the effects of apalutamide dose reduction on skin‐related
adverse events (AEs) and castration‐resistant prostate cancer (CRPC)‐free survival in …
adverse events (AEs) and castration‐resistant prostate cancer (CRPC)‐free survival in …
[HTML][HTML] GLIDR promotes the aggressiveness progression of prostate cancer cells by sponging miR-128–3p
S Li, Y Wang, Q Cao, H Li, Z Zhao, B Wei… - … -Research and Practice, 2023 - Elsevier
Glioblastoma downregulated RNA (GLIDR) is a newly discovered long non-coding RNA
(lncRNA) that its increased expression indicates a poor prognosis of prostate cancer (PCa) …
(lncRNA) that its increased expression indicates a poor prognosis of prostate cancer (PCa) …
Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer
Y Yamamoto, M Nishimoto, Y Akashi, K Kiba… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The therapeutic landscape for metastatic castration-resistant prostate
cancer (mCRPC) has changed dramatically with the introduction of several novel agents …
cancer (mCRPC) has changed dramatically with the introduction of several novel agents …
Clinical outcome and prognostic variables of second-line therapy for patients with castration-resistant prostate cancer after failure of first-line androgen receptor axis …
M Fujiwara, R Fujiwara, T Oguchi, Y Komai… - Anticancer …, 2022 - ar.iiarjournals.org
Background: Despite the rapid introduction of androgen receptor-targeted agents (ARTA)
into clinical practice for castration-resistant prostate cancer (CRPC), the optimal treatment …
into clinical practice for castration-resistant prostate cancer (CRPC), the optimal treatment …
Editorial Comment Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer
MD Takeshi Yuasa - search.ebscohost.com
Abstract Editorial Comment to Predictive factors of survival outcomes in first-line therapy for
metastatic castration-resistant prostate cancer Abiraterone acetate and enzalutamide are …
metastatic castration-resistant prostate cancer Abiraterone acetate and enzalutamide are …
[引用][C] Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
T Yuasa - International Journal of Urology: Official Journal of the …, 2021 - europepmc.org
Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic
castration-resistant prostate cancer. - Abstract - Europe PMC Sign in | Create an account …
castration-resistant prostate cancer. - Abstract - Europe PMC Sign in | Create an account …